Skip to content

Incyte target upped to $185 by Barclays

April 7, 2017

Barclays raised its price target on Incyte (NASDAQ: INCY) to $185.00 (from $135.00) while maintaining a Overweight rating.

Analyst Geoff Meacham raises his PT citing IDO progress and upcoming Olumiant approval. He says his confidence has been increasing with regard to the shifting landscape for epacadostat and upcoming FDA approval of Olumiant.

FY 2017 EPS estimate rises from $0.23 to $0.45, FY 2018 EPS remains at $1.39.


From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: